OBJECTIVES

: HIGH-FLUX DIALYSIS (HFHD) AS ONE EFFECTIVE MODE FOR PROVING ROUTINE-MATINTENANCE HEMODIALYSIS TO PATIENTS WITH END-STAGE RENAL DISEASE(ESRD). IT PROMISED TO BETTER PATIENT'S BETTER HEALTH OUTCOMES. THERE MAY BE OCCASIONS WHEN PROCEDURES OR METERIALS MAY BE UTILIZED THAT COULD PRESERVE COMMUNICATION TO THE KIDNEY AND AVOID POTENTIAL RISKS CONVERSION. WE SEEK TO COMPARE THE COST-EFFECTIVENESS OF HFHD AND LFHD PROCEDURES IN COMPARABLE PATIENT POPULATION.

METHODS

THE HOSPITAL-BASED DATABASE WAS RETROSPECITVELY USED TO ESTIMATE THE COST-EFFECTIVENESS OF HFHD VERSUS LFHD IN CHINA, WHICH PROVIDING DETAILED RESOURCE UTILIZATION AND COST DATA CATERORIZED UNDER A PATIENT'S PRINCIPAL. A TOTAL OF 9560 PATIENTS WITH A PROCEDURE CODE FOR EITHER HFHD (25%0OR LFHD (75%) WERE IDENTIFIED IN YEAR 2018. PROPENSITY SCORE METHODOLOGY WAS USED TO MATCH HFHD PATIENTS TO LFHD PATIENTS BASED ON PATIENT'S DEMOGRAPHICS AND HOSPITAL CHARACTERISTICS.

RESULTS

: MEAN COST WAS SIGNIFICANTLY HIGHER IN HFHD COMPARED TO LFHD, 210,543 RMB VERUS 200,876 RMB PERPATIENT ANNUALLY PERSPECTIVELY, P=0.0004. PATIENTS UNDERGOING HFHD PROCEDURES HAS A SIGNIFICANTLY SHORTER HOSPITAL LENGTH OF STAY, COMPARED TO LFHD, 9 DAYS VERSUS 10.4 DAYS FOR HOSPITALIZATION, PERSPECTIVELY, P<0.001. PREDICTED LIFE EXPECTANCY WITH HFHD WAS SIGNIFICANLT HIGHER (P>0.05).

CONCLUSIONS

: HFHD WAS ASSIOCIATED WITH SHORTER HSOPITAL LENGTHS OF STAY, BETTER HEALTH OUTCOMES, EVEN FOR ONE HIGHER MEAN COSTS WHEN COMPARED TO A MATCHED SET OF PATIENTS UNDERGOING LFHD. THESE FINDINGS SUGGEST THAT ONE FRUTHER STUDY ON LONG TERM COST-EFFECTIVENESS OF ESRAD PATIENTS IS NECESSARY ASSOCIATED WITH HIGHER HEALTH OUTCOMES AND POTENTIAL SAVING MORE MOENY FOR PATIENTS WITH COMPLICATION (E.G. DIABETES).